Drug Discovery World

SEPTEMBER 5, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling. appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Protein Genotype 59

Drug Discovery World

SEPTEMBER 26, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling. Register for free here.

Development 52

Development Drugs Protein Genotype 52

Drug Discovery World

SEPTEMBER 12, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling. Register for free here.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52

Drug Discovery World

AUGUST 25, 2023

However, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. Initial screening of treatments may utilise the highly proliferative Chinese Hamster Ovarian (CHO) or Human Embryonic Kidney (HEK) cell lines with the liver protein(s) of interest exogenously expressed.

Gene Therapy 52

Gene Therapy Gene Development Genotype 52

XTalks

SEPTEMBER 15, 2020

In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

The Pharma Data

MARCH 25, 2021

SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. Premedicate with a 2- or 3-drug combination regimen (e.g., More information about ASCENT is available at [link].

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

Drug Discovery World

MAY 2, 2023

Steve Wowk , VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. Today, scientists leverage this defence mechanism to learn more about the genomic alterations in diseased states as well as the impact of drug treatments on the human genome.

Genome 52

Genome Genomics Gene DNA 52

Drug Discovery World

SEPTEMBER 19, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling. Register for free here.

Gene Therapy 52

Gene Therapy Gene Development Protein 52

Drug Discovery World

OCTOBER 18, 2022

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). . Context .

In-Vitro 52

In-Vitro Genotype Bioavailability Clinical Trials 52

Drug Discovery World

DECEMBER 12, 2023

I look forward to having access to this therapy as quickly as possible.” The post RNA editing oligonucleotide selected for AATD treatment appeared first on Drug Discovery World (DDW).

RNA 52

RNA In-Vivo Genotype Genetics 52

XTalks

DECEMBER 12, 2023

“In some areas, say Alzheimer’s disease, we have growing collections of imaging, gene, cerebrospinal fluid (CSF) and blood markers to follow and look at target engagement of our drugs,” says James Vornov, MD, PhD, Vice President of the Medical Department at Medpace. Furthermore, blood NfL has shown its versatility as a biomarker.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

The Pharma Data

APRIL 7, 2021

Food and Drug Administration (FDA) has granted full approval to Trodelvy ® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. DRUG INTERACTIONS.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

APRIL 14, 2021

The FDA’s accelerated approval mechanism enables drugs that treat serious diseases with unmet medical need to be approved based on a surrogate or intermediate clinical endpoint. Premedicate with a two or three drug combination regimen (e.g., DRUG INTERACTIONS. FOSTER CITY, Calif.–(BUSINESS About Trodelvy.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration to treat mild-to-moderate COVID-19 patients. Eli Lilly’s bamlanivimab targets different sites on the SARS-CoV-2 spike protein. Eli Lilly expanded its ongoing BLAZE-4 study to include Vir’s monoclonal antibody in the trial.

Antibody 52

Antibody Genotype Trials Nurses 52

Drug Discovery World

MARCH 1, 2023

SLAS2020 showed me how technology development fits into the landscape of drug discovery and stimulated me to further explore those possibilities. The post Image-based screening of pooled genetic libraries appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Genome Genomics Genotype 52

The Pharma Data

NOVEMBER 24, 2020

Food and Drug Administration (FDA) approved Oxlumo (lumasiran) injection for subcutaneous use, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Injection site reactions (ISRs) were the most common drug-related adverse reaction.

FDA Approval 52

FDA Approval Production RNA Medicine 52